

27 **ABSTRACT**

28

29 **Background.** The importance of specific serotypes causing invasive pneumococcal disease
30 (IPD) differs by age. Data on pneumococcal carriage in different age groups, along with data
31 on serotype-specific invasiveness, could help to explain these age-related patterns and their
32 implications for vaccination.

33

34 **Methods.** Using pneumococcal carriage and disease data from Israel, we evaluated the
35 association between serotype-specific IPD in adults and serotype-specific carriage
36 prevalence among children in different age categories, while adjusting for serotype-specific
37 invasiveness. We used a sliding window approach to estimate carriage prevalence using
38 different age groupings. Deviance Information Criterion was used to determine which age
39 groupings of carriage data best fit the adult IPD data. Serotype-specific disease patterns
40 were further evaluated by stratifying IPD data by comorbidity status.

41

42 **Results.** The relative frequency of serotypes causing IPD differed between adults and
43 children, and also differed between older and younger adults and between adults with and
44 without comorbidities. Serotypes over-represented as causes of IPD in adults were more
45 commonly carried in older children as compared to younger children. In line with this, the
46 serotype-specific frequency of carriage in older children (aged 36-59 months), rather than
47 infants, best correlated with serotype-specific IPD in adults.

48

49 **Conclusions.** These analyses suggest that older children, rather than infants, are the main
50 drivers of disease patterns in adults. These insights could help in optimizing vaccination
51 strategies to reduce disease burden across all ages.

52 INTRODUCTION

53 *Streptococcus pneumoniae* (pneumococcus) is a frequent colonizer of the upper respiratory
54 tract of healthy children and is also a major cause of disease globally. The burden of
55 pneumococcal disease disproportionately affects infants and the elderly and those with certain
56 underlying comorbidities [1]. Pneumococcal conjugate vaccines (PCVs) provide protection
57 against 10 or 13 of the 90+ immunologically-distinct polysaccharide capsular types
58 (serotypes), preventing disease and reducing colonization of the nasopharynx in vaccinated
59 individuals. Since children who carry pneumococcus are the main source of exposure for
60 adults [2–4], vaccinating children with PCVs has also resulted in the near-elimination of
61 invasive pneumococcal disease (IPD) caused by vaccine-targeted serotypes (VTs) among
62 adults [5].

63

64 Even before the introduction of PCVs, there were important differences in the distribution of
65 serotypes causing IPD between children and adults [6]. For instance, VTs caused a larger
66 fraction of IPD in children. After introduction of PCVs, non-vaccine serotypes (NVTs) have
67 increased in frequency among colonized children. This “serotype replacement” [7] has had a
68 modest effect on IPD rates in children but has substantially reduced the indirect benefits for
69 adults that result from vaccinating infants. Older adults and those with certain underlying
70 diseases have proven particularly susceptible to disease caused by emerging NVTs [8–10].
71 In some countries, the increase in the incidence of NVTs in adults has offset declines in the
72 incidence of VTs [11].

73

74 Variations in vaccine approach and schedule could have important implications for
75 preventing IPD in adults. Currently, the number and timing of doses used in children differs
76 between countries, as does the use of a booster dose. For instance, the United Kingdom
77 recently decided to move to a reduced-dose schedule of PCVs in infants, where children
78 receive a single priming dose and a single booster dose [12]. For such a strategy to be
79 effective in maintaining indirect protection of unvaccinated individuals, it is important that

80 vaccine-derived protection is maintained among the children responsible for transmission in
81 the population. Thus, identifying those age groups driving transmission is critical. Moreover,
82 these issues are increasingly important as new 15- and 20-valent conjugate vaccines move
83 towards licensure.

84

85 It is generally assumed that most exposure to pneumococcus in adults results from contact
86 with children [13]. However, children are not all equally likely to carry and transmit
87 pneumococcus, and some groups of children (e.g., preschoolers) might be more influential
88 due to different contact patterns and intensity of carriage [13–15]. Recent work suggests that
89 older children, rather than infants, transmit pneumococcus to adults [13–15].

90

91 In this study, we sought to understand drivers of the variations in the distribution of serotypes
92 causing IPD by age and in those with and without comorbidities. We evaluated variations in
93 the serotype distribution in IPD by age and comorbidity, and we tested which age groups of
94 children had serotype patterns in carriage that were most closely correlated with IPD rates in
95 adults. These analyses could help in optimizing vaccine strategies to reduce pneumococcal
96 disease across all age groups.

97

98

99 **METHODS**

100

101 **Data sources**

102 PCV7 was introduced in Israel in July 2009 using a 2+1 schedule with a catch-up campaign
103 for children <24 months of age. PCV7 was replaced in the schedule by PCV13 starting in
104 November 2010 (without a catch-up). Details of the carriage and IPD data used in this study
105 have been previously described [14,16,17]. Briefly, the carriage data were collected from
106 children visiting the emergency department (ED) at Soroka University Medical Center, the
107 only emergency department in southern Israel. The first 4 Jewish and first 4 Bedouin

108 children <5 years of age visiting the ED each day for any complaint were enrolled in the
109 study to obtain a nasopharyngeal swab. IPD data were obtained from a nationwide
110 surveillance system [16,18]. The carriage and IPD studies were approved by the Sheba
111 Medical Center and the Soroka University Medical Center Institutional Review Boards (IRB).
112 Data in the current study was de-identified before analysis.

113

114 Carriage and disease data were divided into 4 equal time periods (Early-PCV7: November
115 2009 to July 2011, Early PCV13: August 2011 to February 2013, Late-PCV13: March 2013
116 to October 2014, Stable-Post-PCV period: November 2014 to June 2016). IPD data from
117 4,304 individuals were stratified by age group (<5 [n=1,180], 5-17 [n=299], 18-39 [n=407],
118 40-64, [n=943] 65-79 [n=816], 80+ [n=658] years) and according to comorbidity status (no
119 risk, at risk, or high risk for pneumococcal disease [18]) based on recommendations for
120 receipt of PPV23. Risk group analyses were conducted on individuals aged 18+ years who
121 had information on comorbidity status, serotype, and sample collection date. Period 4 for the
122 subset of data with comorbidities ended December 2015 (as compared to June 2016 for the
123 full dataset).

124

125 The carriage data were stratified by both ethnicity (Jewish versus Bedouin) and according to
126 presence or absence of recorded complaints that could be caused by pneumococcus
127 (bacteremia, conjunctivitis, influenza, LRI, meningitis, otitis media, pneumonia, sepsis, URI)
128 to confirm results were not sensitive to these factors.

129

130 **Modeling the relationship between carriage in children and invasive disease in adults**

131 The goal for these analyses was (1) to evaluate variations in serotype-specific IPD incidence
132 by age and (2) to determine whether carriage data from specific age groups better correlated
133 with IPD incidence. To do this, we used a previously-described Poisson regression model
134 [19]. The outcome variable was the number of IPD cases caused by each serotype in the
135 relevant age group and time period. The covariates in this initial model were the serotype-

136 specific carriage prevalence in the corresponding time period in Jewish children <5 years of
137 age (log transformed) and the serotype-specific invasiveness for children (log-transformed).
138 A serotype-specific random intercept was included to account for unexplained serotype-
139 specific variations in IPD rates. This random intercept can be interpreted as a log(rate ratio)
140 which indicates how much more or less disease was caused by that serotype in adults
141 based on the carriage prevalence in children and invasiveness patterns in children. Analyses
142 were stratified by age or by co-morbidity status. To account for uncertainty in the predictors
143 (serotype-specific carriage and invasiveness when sparse serotype-specific data is
144 available), we fit this model within a Bayesian framework. Further details on the model
145 structure and the priors are reported in [19].

146

147 Serotype-specific invasiveness estimates for children <5 years of age, and their uncertainty,
148 were estimated using a separate Bayesian statistical model [19]. Invasiveness was
149 calculated by dividing serotype-specific IPD incidence by the serotype-specific carriage
150 prevalence in <5 year olds [20]. The hierarchical structure of this model effectively allowed
151 us to obtain an estimate of invasiveness (with uncertainty) even for serotypes with few cases
152 of disease or few carriers. The models were fit using JAGS v4.2.0 [21] in RStudio v1.0.143
153 [22], using R v3.5.1 (<https://www.r-project.org/>).

154

155 Because the IPD data were primarily available for the Jewish population, only carriage and
156 IPD data from Jewish residents were used in the subsequent analyses.

157

158 **Stratification of carriage in children by age group to better explain adult IPD patterns**

159 The goal for this analysis was to determine whether serotype-specific carriage prevalence in
160 any particular age group better explained patterns of IPD observed in adults and in different
161 risk groups. To accomplish this, the carriage data from Jewish children were further stratified
162 by age category (≤ 12 months, <18 months, <24 months, <36 months, 13-59 months, 18-59
163 months, 24-59 months, and 36-59 months; **Table 1**). The models of IPD described above

164 were re-fit using these subsets of carriage prevalence data. Deviance Information Criteria
165 (DIC) was computed for each model [23]. This Bayesian model comparison metric accounts
166 for the fit of the model to the data while penalizing more complex models. A lower DIC value
167 for a model among a group of competitors indicates that it has an improved balance between
168 model fit and complexity.

169

170

171 **RESULTS**

172

173 **Characteristics of the data**

174 Nasopharyngeal swabs from 10,379 individuals <5 years of age were collected between
175 November 2009 and June 2016. Of these, 48% tested positive for pneumococcal carriage.
176 Prevalence was higher in Bedouin children and among those presenting with a complaint
177 that could potentially have been caused by pneumococcus (e.g., otitis media, pneumonia)
178 (**Table 1**). Carriage prevalence increased through the first year of life, then stabilized,
179 declining slightly after 48 months of age in both study populations, though more sharply in
180 Jewish children (**Supplementary Figure S1**). More swabs were collected from younger than
181 older children (**Supplementary Figure S2**). The serotype distribution was broadly similar in
182 pneumococcal-positive swabs obtained from children with respiratory complaints and those
183 obtained from children without respiratory complaints (**Supplementary Figure S3**). There
184 were some differences in serotype distribution between Jewish and Bedouin children
185 (**Supplementary Figure S4**). For instance, serotype 23A was more common in Jewish
186 children in periods 2-4 and 17F more common in Bedouin children.

187

188 There were 4,303 cases of IPD among individuals >5 years of age, with 1,474 (34%) ≥65
189 years of age. Of those aged 18 years and older, 2,347 individuals had a recorded
190 comorbidity status (no risk, at risk, or high risk for pneumococcal disease [18]) based on
191 recommendations for receipt of PPV23

192

193 **Variations in serotype-specific disease patterns by age and comorbidity group**

194 For most serotypes, the observed IPD incidence in adults was similar to what would be
195 expected based on the carriage prevalence and invasiveness estimates from children <5
196 years of age (random intercept close to zero) (**Figure 1**, results for adults aged 80 years and
197 older; **Supplementary Figure S5**, results for all age groups). Some serotypes however,
198 caused more disease in certain age groups compared to what would be expected based on
199 carriage patterns in children (random intercepts above zero). This was notable for serotype
200 1, which was most over-represented among 5-17 year olds (with similar patterns observed
201 for serotypes 2 and 17F), and serotype 8, which was most represented among 18-39 year
202 olds (**Figure 2**). Both serotypes demonstrated declining gradients with older age, where the
203 number of IPD cases in older age groups was closer to the expected level. In contrast,
204 serotypes 3, 6C, 15A and 31 were over-represented as causes of IPD more among older
205 adults than among younger adults. Conversely, serotypes 21 and 27 were under-
206 represented as causes of disease in all adults >40 years of age.

207

208 Similar patterns were seen when stratifying by comorbidity status (**Supplementary Figures**
209 **S6 and S7**). For instance, serotype 3 and 8 were over-represented in adults with and without
210 comorbidities, but the effect was more dramatic in those with comorbid conditions. Likewise,
211 serotype 8 was most notable among those without comorbid conditions. We also considered
212 whether the age or comorbidity patterns were confounding each other. Even after stratifying
213 by comorbidity and by age, some serotypes, and particularly serotype 3, were still over-
214 represented among older adults (**Supplementary Figure S8**).

215

216 **Serotype prevalence in carriage differs between younger and older children**

217 We next compared the prevalence of serotypes colonizing children <24 months of age
218 versus those carried by children 24-59 months of age (**Figure 3**). Serotypes 5, 1, 7F, 3, 27,
219 33A, 6D, 35A, 23F, 14, 34, 18C, 22F, 12A, 24A, 37, 4, 20, 31, 19A were all at least 50%

220 more prevalent in children 24-59 months of age than in those <24months of age. In contrast,
221 serotypes 6A, 10A, 13, 19F, and 21 were at least 25% less prevalent in the children aged
222 24-35 months.

223

224 Comparing the serotypes that were more prevalent in carriage in older versus younger
225 children with the serotypes that were over-represented as causes of IPD in adults, several
226 serotypes at the extremes stand out (**Figure 4**). In particular, serotype 1 was carried more in
227 the older children than in the younger children and was also among the most over-
228 represented serotypes causing IPD among the 5-17 and 18-39 year old adults. Likewise,
229 serotype 3 was more common in carriage among older children and was over-represented
230 as a cause of disease among adults 40+ years of age.

231

232 While we did not have adult carriage data from Israel, previous studies from the Netherlands
233 have collected carriage data from both children [24] and adults [25]. Notably, there was a
234 correlation between the serotypes that were over-represented as causes of IPD in adults in
235 Israel and the serotypes that were more common among adult carriers compared with
236 pediatric carriers in the Netherlands (**Supplementary Figure S9**). In addition, serotypes that
237 were over-represented as causes of IPD in adults in Israel were also those over-represented
238 as causes of IPD in adults in the Netherlands (as compared to <5 year olds) [10], both prior
239 to and following PCV-implementation (**Supplementary Figure S10**). Interestingly, these
240 correlations were stronger when comparing all adults >65 years of age in the Netherlands to
241 adults aged 65-79 years in Israel than when compared to all adults aged >65 years in Israel,
242 perhaps reflecting some differences between the older age groups in these two countries.

243

244 **Serotype-specific patterns of carriage in older children best correlate with IPD in**
245 **adults**

246 We considered whether carriage prevalence in certain age groups better correlated with IPD
247 in adults, after adjusting for invasiveness. Rather than using arbitrary age groupings, we

248 calculated serotype-specific prevalence for age-bins of different widths. We then evaluated
249 which of these age groupings best correlated with the patterns of serotype-specific IPD in
250 older ages groups. DIC scores obtained from each model demonstrated that serotype
251 patterns in carriage among 36-59 month old children best explained serotype-specific IPD
252 patterns in all of the adult age groups (**Table 2**). Serotype patterns in 24-59 month old
253 children also correlated well with serotype-specific IPD patterns in children and young adults.
254 Patterns were consistent when stratifying by those with or without respiratory complaints.

255

256

257 **DISCUSSION**

258 While the serotypes colonizing children are broadly similar around the world, the serotypes
259 causing disease in children and adults vary between age groups and settings [6,26].
260 Although children <5 years of age are often considered as a single homogenous group when
261 evaluating carriage patterns, our analyses demonstrate that serotype prevalence differs by
262 age. Among the Jewish population in Israel, serotype-specific carriage patterns differ
263 between children <24 months of age and those 24-59 months of age, and the patterns in
264 older children better correlated with patterns of IPD in adults. This finding, along with recent
265 work evaluating the post-vaccine trajectories of carriage and IPD [14], suggests that
266 preschoolers might play a more important role in transmission to adults than infants and
267 toddlers. This has important implications when considering the possible public health impact
268 of different dosing schedules and the timing of booster doses. If older children are important
269 for transmission, then it is critical to ensure that they are protected adequately against
270 colonization.

271

272 Importantly, these results highlight that serotype-specific IPD patterns in adults do not
273 always reflect carriage patterns in children (considered the reservoir of pneumococcus in the
274 population). For example, the current high rates of IPD in adults that started in 2015/16
275 caused by serotypes 8 and 12F were not predicted by carriage surveillance in children in

276 England and Wales [11], nor in the Netherlands [27]. For any strategy aiming to prevent
277 pneumococcal disease, the presence of a large pneumococcal reservoir in older children or
278 adults is an essential factor to consider. Carriage-based surveillance should be designed to
279 address this possibility and to include older children or adults when the goal is to understand
280 or predict indirect effects of PCVs. Further work is needed to understand the implications of
281 these serotype/age patterns for vaccination strategies.

282

283 This study focused on the Jewish population in Israel, a population with relatively low
284 transmission of pneumococcus. In this population, the older children attending daycare or
285 preschool have more opportunities for transmission than those at home in isolation
286 (predominantly infants) [13,15]. The situation could differ in populations with higher intensity
287 transmission [28]. Populations with higher intensity transmission tend to have a higher
288 residual burden of vaccine targeted serotypes [28].

289

290 The intensity of transmission might also influence the age distribution of serotypes in
291 carriage, and subsequently, in disease. A population with higher intensity transmission would
292 lead to earlier first carriage episodes and more frequent exposure, as has previously been
293 observed in Bedouin versus Jewish children in Israel [29]. An earlier age distribution of
294 carriage in a high transmission setting leads to stronger immunity against the dominant
295 strains (negative frequency dependent selection [30]), potentially allowing the weaker
296 serotypes to colonize older children who are more important for transmission. Conversely, in
297 a low transmission setting, the immunity against the dominant serotypes might be lower,
298 meaning that weaker serotypes are pushed to a later age when general immunity against
299 pneumococcus is high, effectively restraining them within the population. The introduction of
300 vaccines against the dominant serotypes can shift the age distribution of sub-dominant
301 serotypes, influencing disease patterns in adults.

302

303 Serotypes over-represented as cause of disease in younger adults were also over-
304 represented in adults considered low risk of pneumococcal disease and *vice versa*, but the
305 patterns differed by serotype. For instance, serotypes 1 and 3 had opposite patterns among
306 adults. Serotype 1 was most over-represented in younger individuals and those without co-
307 morbidities, and serotype 3 was most over-represented in older age groups. Serotype 1 has
308 previously been reported to more commonly affect younger individuals, appearing to have
309 only brief periods of colonization before causing disease, while also primarily infecting
310 previously healthy individuals (in line with younger age) [31]. For this reason, it has been
311 described to act as a “primary pathogen” [31]. When stratifying <18 year olds into smaller
312 age groups, this association with young age was not due to higher rates in 5-10 year olds
313 but rather in the older portion of this group. This points to something specific to the 10-18
314 year old lifestyle, promoting high circulation, perhaps similar to what is observed for
315 meningococcal disease. With such short periods of colonization, one could expect very few
316 transmission opportunities to parents and even less (and therefore between) elderly
317 individuals (who with younger exposure may also be better protected). In line with this,
318 higher incidence of serotype 1 disease is seen in areas of intense transmission (crowding).

319

320 In conclusion, we identified age-related differences in serotype-specific disease, with certain
321 serotypes over- or under-represented in different age groups but also co-morbidity status.
322 These differences are likely explained by differences in susceptibility or exposure to specific
323 serotypes; enhanced carriage data from older children or adults and elderly would help to
324 further understand these patterns. These findings hold importance for those considering new
325 vaccination strategies for infants and for the next generation of adult-specific pneumococcal
326 vaccinations. This issue will gain urgency as current vaccine-serotypes continue to decline
327 and non-vaccine-serotypes increase as cause of disease in adults.

328

329

330 **DECLARATIONS**

331

332 **Competing interests.** ALW declares to have received consulting fees for participation in
333 advisory boards for Pfizer. GRY has received consulting fees and research funding from
334 Pfizer and research support from GSK. RD has received consulting fees from Pfizer, MSD
335 and MeMed; research grants from Pfizer and MSD; and speaker fees from Pfizer. DMW has
336 received consulting fees from Pfizer, Merck, GSK, and Affinivax and has received research
337 funding through grants from Pfizer to Yale. All other co-authors declare no potential conflict
338 of interest.

339

340 **Funding.** This work was supported by the National Institutes of Health/National Institute of
341 Allergy and Infectious Diseases [grant numbers R01-AI123208, R01-AI137093 to D.M.W];
342 and the Bill and Melinda Gates Foundation [grant number OPP1176267 to D.M.W]. The
343 funding agencies were not involved in the design and conduct of the study; collection,
344 management, analysis, and interpretation of the data; preparation, review, or approval of the
345 manuscript; and decision to submit the manuscript for publication. The corresponding author
346 had full access to all the data in the study and had final responsibility for the decision to
347 submit for publication.

348

349 **Author's contributions.** RD and DMW conceived the study. GRY, NGL, RD and DMW
350 managed the study and collected the data. ALW, JLW, GRY and DMW performed the
351 analyses and interpreted the data. ALW and DMW drafted the manuscript. All authors
352 amended and commented on the final manuscript.

353

354

355 REFERENCES

356 1. Jansen AGSC, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal
357 disease among adults: associations among serotypes, disease characteristics, and
358 outcome. Clin Infect Dis **2009**; 49:e23-9.

- 359 2. Wyllie AL, Rümke LW, Arp K, et al. Molecular surveillance on *Streptococcus*
360 *pneumoniae* carriage in non-elderly adults; little evidence for pneumococcal
361 circulation independent from the reservoir in children. *Sci Rep* **2016**; 6:34888.
- 362 3. Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O'Brien KL. The fundamental
363 link between pneumococcal carriage and disease. *Expert Rev Vaccines* **2012**;
364 11:841–55.
- 365 4. Auranen K, Mehtälä J, Tanskanen A, S Kalso M, Kalso MS. Between-strain
366 competition in acquisition and clearance of pneumococcal carriage--epidemiologic
367 evidence from a longitudinal study of day-care children. *Am J Epidemiol* **2010**;
368 171:169–76.
- 369 5. Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive
370 pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled
371 analysis of multiple surveillance sites. *PLoS Med* **2013**; 10:e1001517.
- 372 6. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among
373 pneumococcal serotypes. *Lancet Infect Dis* **2005**; 5:83–93.
- 374 7. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after
375 pneumococcal vaccination. *Lancet* **2011**; 378:1962–73.
- 376 8. Scott JR, Millar E V, Lipsitch M, et al. Impact of more than a decade of pneumococcal
377 conjugate vaccine use on carriage and invasive potential in Native American
378 communities. *J Infect Dis* **2012**; 205:280–8.
- 379 9. Wagenvoort GHJ, Sanders EAM, Vlaminckx BJ, et al. Invasive pneumococcal
380 disease: Clinical outcomes and patient characteristics 2–6 years after introduction of
381 7-valent pneumococcal conjugate vaccine compared to the pre-vaccine period, the
382 Netherlands. *Vaccine* **2016**; 34:1077–1085.
- 383 10. van Deursen AMM, van Mens SP, Sanders EAM, et al. Invasive pneumococcal
384 disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. *Emerg Infect*
385 *Dis* **2012**; 18:1729–37.
- 386 11. Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes

- 387 causing invasive pneumococcal disease in England and Wales, 2000–17: a
388 prospective national observational cohort study. *Lancet Infect Dis* **2018**; 18:441–451.
- 389 12. Flasche S, Van Hoek AJ, Goldblatt D, et al. The Potential for Reducing the Number of
390 Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-
391 Income Countries. *PLoS Med* **2015**; 12:e1001839.
- 392 13. Nurhonen M, Cheng AC, Auranen K. Pneumococcal transmission and disease in
393 silico: a microsimulation model of the indirect effects of vaccination. *PLoS One* **2013**;
394 8:e56079.
- 395 14. Weinberger DM, Pitzer VE, Regev-Yochay G, Givon-Lavi N, Dagan R. Association
396 Between the Decline in Pneumococcal Disease in Unimmunized Adults and Vaccine-
397 Derived Protection Against Colonization in Toddlers and Preschool-Aged Children.
398 *Am J Epidemiol* **2019**; 188:160–168.
- 399 15. Althouse BM, Hammitt LL, Grant L, et al. Identifying transmission routes of
400 *Streptococcus pneumoniae* and sources of acquisitions in high transmission
401 communities. *Epidemiol Infect* **2017**; 145:2750–2758.
- 402 16. Regev-Yochay G, Paran Y, Bishara J, et al. Early impact of PCV7/PCV13 sequential
403 introduction to the national pediatric immunization plan, on adult invasive
404 pneumococcal disease: A nationwide surveillance study. *Vaccine* **2015**; 33:1135–
405 1142.
- 406 17. Ben-Shimol S, Givon-Lavi N, Greenberg D, Dagan R. Pneumococcal nasopharyngeal
407 carriage in children <5 years of age visiting the pediatric emergency room in relation
408 to PCV7 and PCV13 introduction in southern Israel. *Hum Vaccines Immunother* **2016**;
409 12:268–276.
- 410 18. Regev-Yochay G, Katzir M, Strahilevitz J, et al. The herd effects of infant
411 PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six
412 years post implementation; a nationwide study in Israel. *Vaccine* **2017**; 35:2449–
413 2456.
- 414 19. Weinberger DM, Grant LR, Weatherholtz RC, Warren JL, O'Brien KL, Hammitt LL.

- 415 Relating Pneumococcal Carriage Among Children to Disease Rates Among Adults
416 Before and After the Introduction of Conjugate Vaccines. *Am J Epidemiol* **2016**;
417 183:1055–1062.
- 418 20. Smith T, Lehmann D, Montgomery J, Gratten M, Riley ID, Alpers MP. Acquisition and
419 invasiveness of different serotypes of *Streptococcus pneumoniae* in young children.
420 *Epidemiol Infect* **1993**; 111:27–39.
- 421 21. Plummer M, Stukalov A, Denwood M. Bayesian Graphical Models using MCMC.
422 2018.
- 423 22. RStudio-Team. RStudio: integrated development for R. RStudio, Inc. 2016.
- 424 23. Spiegelhalter DJ, Best NG, Carlin BP, van der Linde A. Bayesian measures of model
425 complexity and fit. *J R Stat Soc Ser B (Statistical Methodol)* **2002**; 64:583–639.
- 426 24. Wyllie AL, Wijmenga-Monsuur AJ, van Houten MA, et al. Molecular surveillance of
427 nasopharyngeal carriage of *Streptococcus pneumoniae* in children vaccinated with
428 conjugated polysaccharide pneumococcal vaccines. *Sci Rep* **2016**; 6:23809.
- 429 25. Krone CL, Wyllie AL, van Beek J, et al. Carriage of *Streptococcus pneumoniae* in
430 Aged Adults with Influenza-Like-Illness. *PLoS One* **2015**; 10:e0119875.
- 431 26. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups
432 cause the most invasive disease: implications for conjugate vaccine formulation and
433 use, part I. *Clin Infect Dis* **2000**; 30:100–21.
- 434 27. Vissers M, Wijmenga-Monsuur AJ, Knol MJ, et al. Increased carriage of non-vaccine
435 serotypes with low invasive disease potential four years after switching to the 10-
436 valent pneumococcal conjugate vaccine in The Netherlands. *PLoS One* **2018**;
437 13:e0194823.
- 438 28. Lourenço J, Obolski U, Swarthout TD, et al. Determinants of high residual post-
439 PCV13 pneumococcal vaccine type carriage in Blantyre, Malawi: a modelling study.
440 *bioRxiv* **2019**; :477695.
- 441 29. Lewnard JA, Huppert A, Givon-Lavi N, et al. Density, Serotype Diversity, and Fitness
442 of *Streptococcus pneumoniae* in Upper Respiratory Tract Cocolonization With

- 443 Nontypeable Haemophilus influenzae. J Infect Dis **2016**; 214:1411–1420.
- 444 30. Corander J, Fraser C, Gutmann MU, et al. Frequency-dependent selection in vaccine-
445 associated pneumococcal population dynamics. Nat Ecol Evol **2017**; 1:1950–1960.
- 446 31. Sjöström K, Spindler C, Ortqvist a, et al. Clonal and capsular types decide whether
447 pneumococci will act as a primary or opportunistic pathogen. Clin Infect Dis **2006**;
448 42:451–9.
- 449
- 450

Table 1. Characteristics of the Data		
	Total number of swabs collected, n	Number of swabs positive for pneumococcus, n (%)
All	10379	4957 (48)
Jewish	4464	1900 (43)
<12 months	1862	717 (39)
<18 months	2491	1006 (44)
<24 months	3082	1295 (43)
<36 months	3757	1611 (43)
13-59 months	2602	1183 (45)
18-59 months	1973	894 (45)
24-59 months	1382	605 (44)
36-59 months	707	289 (41)
Bedouin	5915	3057 (52)
Respiratory complaint	4279	2194 (51)
Without respiratory complaint	6118	2763 (45)

It is made available under a [CC-BY 4.0 International license](#) .

451


It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/) .

Table 2. Deviance Information Criteria (DIC) for each model which varied by Jewish child age group

	≤5 years	5-17 years	18-39 years	40-64 years	65-79 years	≥80 years
Overall carriage data	431.34	548.46	525.97	502.32	500.12	541.80
≤12m	372.05	498.34	480.88	462.45	480.29	517.08
<18m	390.27	519.60	502.09	483.37	504.06	528.75
<24m	405.89	538.67	506.53	495.84	483.53	531.24
<36m	437.15	539.01	531.78	508.30	495.63	535.28
13-59m	409.54	593.61	516.02	489.72	489.30	528.40
18-59m	376.82	519.78	492.94	450.96	482.43	527.10
24-59m	357.72	479.66	468.79	443.35	471.71	513.82
36-59m	313.42	425.54	407.27	386.70	433.85	444.09


452

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



453

454 **Figure 1. Over-representation of serotypes causing IPD in older adults.** The numbers
455 denote serotype-specific random intercepts from a model fit to IPD data from 80+ year old
456 adults in Israel. Values above zero indicate that the serotype is over-represented as a cause
457 of IPD in this age group based on how frequently they are carried in children <5 years of age
458 and their invasiveness in <5 year olds. Values below zero indicate the serotype is under-
459 represented in IPD. For each serotype the 95% (thinner line) and 68% (thicker line) credible
460 intervals are shown. PCV13 vaccine serotypes are denoted by *.



461

462 **Figure 2. Over-representation of serotypes causing IPD in different age groups.** The
463 colors reflect serotype-specific random intercepts from a model fit to IPD data from different
464 age groups in Israel. Darker red represents serotypes in that age strata over-represented as
465 causes of IPD based on how frequently they are carried in children <5 years of age and their
466 invasiveness in <5 year olds. Darker blue indicates serotypes under-represented as causes

467 of IPD in that age group. Symbols on the left highlight age-related patterns for certain
468 serotypes. Those denoted by * become increasingly over-represented with increasing host
469 age, those denoted by & became increasingly under-represented with increasing host age
470 and serotypes denoted by # are more over-represented in younger individuals.


471

472

473

474

475



476

477 **Figure 3. Ratio of serotype-specific carriage prevalence in children aged 24-59 months**
478 **of age compared to children aged under 24 months.**

479

480

481


482

483

484

485

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



487 **Figure 4. Comparison of serotypes over-represented in IPD in adults with the carriage**
488 **patterns between older and younger children.** The values on the x-axis are the serotype-
489 specific random intercept, which are a measure of how over-represented the serotype is as a
490 cause of IPD in adults. The values on the y-axis denote the serotype-specific log-ratio of
491 prevalence in Jewish children aged >24 months as compared to <24 month olds. Circle size
492 was calculated from the square root of IPD cases, with circle color darkening towards red
493 also denoting higher IPD incidence

494

495

496

497 **SUPPLEMENTARY FIGURE LEGENDS**

498

499 **Supplementary Figure S1.** Pneumococcal carriage prevalence by age for Bedouin (red)
500 and Jewish (blue) children.

501

502 **Supplementary Figure S2.** Age distribution of (A) all swabs obtained in the current study for
503 determination of pneumococcal carriage prevalence and (B) for those which tested positive
504 for *Streptococcus pneumoniae*.

505

506 **Supplementary Figure S3.** Serotype-specific carriage prevalence in swabs obtained from
507 children with a respiratory-related complaint as compared to those without a respiratory
508 complaint, per study period.

509

510 **Supplementary Figure S4.** Serotype-specific carriage prevalence in swabs obtained from
511 Bedouin children as compared to Jewish children, per study period.

512

513 **Supplementary Figure S5. Over-representation of serotypes causing IPD in different**
514 **age groups of adults.** The numbers denote serotype-specific random intercepts from a

515 model fit to IPD data from 80+ year old adults in Israel. Values above zero indicate that the
516 serotype is over-represented as a cause of IPD in this age group based on how frequently
517 they are carried in children <5 years of age and their invasiveness in <5 year olds. Values
518 below zero indicate the serotype is under-represented in IPD. For each serotype the 95%
519 (thinner line) and 68% (thicker line) credible intervals are shown.

520

521 **Supplementary Figure S6. Over-representation of serotypes causing IPD for**
522 **individuals over 18 years of age, stratified according to comorbidity status (no risk, at**
523 **risk, or high risk for pneumococcal disease) based on recommendations for receipt of**
524 **PPV23.** The numbers denote serotype-specific random intercepts from a model fit to IPD
525 data from 80+ year old adults in Israel. Values above zero indicate that the serotype is over-
526 represented as a cause of IPD in this age group based on how frequently they are carried in
527 children <5 years of age and their invasiveness in <5 year olds. Values below zero indicate
528 the serotype is under-represented in IPD. For each serotype the 95% (thinner line) and 68%
529 (thicker line) credible intervals are shown.

530

531 **Supplementary Figure S7. Heatmap constructed from serotype-specific random**
532 **intercepts based on carriage and IPD data from Jewish children for individuals aged**
533 **18+ years, stratified by comorbidity status (no risk, at risk, or high risk for**
534 **pneumococcal disease) based on recommendations for receipt of PPV23.** Darker blue
535 represents serotypes in that risk strata under-represented in IPD as expected based on
536 carriage and disease data from children; darker red represents serotypes in that risk strata
537 over-represented in IPD. Serotypes over-represented as cause of disease in younger adults
538 were also over-represented in individuals considered low risk (#). Conversely, serotypes
539 which were over-represented in older adults were over-represented in all risk groups (*).
540 Serotypes under-represented in all adults age groups as compared to based on carriage and
541 disease in children were also under-represented in all risk groups (&).

542

543 **Supplementary Figure S8. Heatmap constructed from serotype-specific random**
544 **intercepts based on carriage and IPD data from Jewish children for all adult age**
545 **groups over 18 years of age, stratified by both age and co-morbidity status.** Darker
546 blue represents serotypes in that age- and risk-strata under-represented in IPD as expected
547 based on carriage and disease data from children; darker red represents serotypes in that
548 age- and risk-strata over-represented in IPD. Certain serotypes were over-represented as
549 cause of disease in both younger and healthier individuals (#), or just younger individuals
550 regardless of risk status (&). Conversely, other serotypes remained prominent as cause of
551 disease in older age groups, regardless of risk status (*).

552

553 **Supplementary Figure S9.** Serotype-specific random effects for adults aged 65 years and
554 older from Israel were compared to the ratio of serotype-specific carriage prevalence in
555 adults over 50 years of age vs that in children under 5 years of age in the Netherlands, both
556 prior to and following the introduction of PCV7 into the Dutch National Immunization
557 Program.

558

559 **Supplementary Figure S10.** Serotype-specific random effects for adults over 65 years of
560 age from Israel were compared to the ratio of serotype-specific disease in adults over 50
561 years of age and children under 5 years of age in the Netherlands, both (A) prior to and (B)
562 following the introduction of PCV7 into the Dutch National Immunization Program. Serotypes
563 over-represented as cause of disease in older adults from Israel were also those over-
564 represented in IPD in older adults in the Netherlands.

565